AYTU BioPharma, Inc. logo

AYTU BioPharma, Inc. (AYTU) Q4 2024 Earnings

AYTU·Reported February 12, 2025·After market close

AYTU BioPharma, Inc. reported Q4 2024 revenue of $16.2M, missed analyst consensus of $17.6M by $1.4M. Diluted EPS came in at $-0.28.

Revenue
$16.2Mmissed by $1.4M
Consensus: $17.6M
Diluted EPS
$-0.28met estimate
Consensus: $-0.28
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001437749-25-003568

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about AYTU BioPharma, Inc.'s Q4 2024 earnings report.

AYTU BioPharma, Inc. (AYTU) reported Q4 2024 earnings on February 12, 2025 after market close.

AYTU BioPharma, Inc. reported revenue of $16.2M and diluted EPS of $-0.28 for Q4 2024.

Revenue missed the consensus estimate of $17.6M by $1.4M. EPS beat the consensus estimate of $-0.28 by $0.00.

You can read the 10-Q periodic report (0001437749-25-003568) directly on SEC EDGAR. The filing index links above go to sec.gov.